Close Menu

NEW YORK (GenomeWeb) – The Australian Genomic Cancer Medicine Program has won A$50 million ($36.6 million) in funding from the Australian government, the Garvan Institute of Medical Research said yesterday.

The program, developed at the Garvan Institute, matches patients with rare and uncommon cancers to therapies based on their genome information. Originally funded with A$7 million from the New South Wales government, the program has served more than 1,000 patients since 2016.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.